NovaBay Pharmaceuticals, Inc. (NYSE:NBY) has a beta value of 3.89 and has seen 2,973,558 shares traded in the recent trading session. The company, currently valued at $29.31 Million, closed the recent trade at $0.878 per share which meant it lost $0 on the day or 1.2% during that session. The NBY stock price is -139.18% off its 52-week high price of $2.1 and 72.67% above the 52-week low of $0.24. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.48 Million shares traded. The 3-month trading volume is 4.89 Million shares.

The consensus among analysts is that NovaBay Pharmaceuticals, Inc. (NBY) is a Buy stock at the moment, with a recommendation rating of 1.5. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 2 have rated it as a Hold, with 2 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.05.

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) trade information

Sporting 2.22% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Thursday, Jun 18 when the NBY stock price touched $0.94 or saw a rise of 5.84%. Year-to-date, NovaBay Pharmaceuticals, Inc. shares have moved 38.3%, while the 5-day performance has seen it change 3.07%. Over the past 30 days, the shares of NovaBay Pharmaceuticals, Inc. (NYSE:NBY) have changed 3.8%. Short interest in the company has seen 166.68 Million shares shorted with days to cover at 34.09.

Wall Street analysts have a consensus price target for the stock at $2.25, which means that the shares’ value could jump 156.26% from current levels. The projected low price target is $1.5 while the price target rests at a high of $3. In that case, then, we find that the current price level is +241.69% off the targeted high while a plunge would see the stock lose 70.84% from current levels.

NovaBay Pharmaceuticals, Inc. (NBY) estimates and forecasts

Figures show that NovaBay Pharmaceuticals, Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +51.76% over the past 6 months, with this year growth rate of -54.17%, compared to 13.3% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 64.3% and -500% for the next quarter. Revenue growth from the last financial year stood is estimated to be +54%.

2 analysts offering their estimates for the company have set an average revenue estimate of $2.85 Million for the current quarter. 2 have an estimated revenue figure of $2.33 Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $1.65 Million and $1.61 Million respectively for this quarter and the next, and analysts expect sales will grow by 72.7% for the current quarter and 44.3% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +42.4% over the past 5 years. Earnings growth for 2020 is a modest -25.3% while over the next 5 years, the company’s earnings are expected to increase by 0%.